Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases

Autoimmunity Reviews

Volumn 16, Issue 9, 2017, Pages 885-896

  Li, You ^a   Tang, Ruqi ^a   Leung, Patrick S C ^b   Gershwin, M Eric ^b   Ma, Xiong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmune cholestatic liver diseases; Bile acids; Intestinal microbiota

Indexed keywords

BICARBONATE; BILE ACID; CARRIER PROTEIN; CELL NUCLEUS RECEPTOR; FARNESOID X RECEPTOR; G PROTEIN COUPLED RECEPTOR; OBETICHOLIC ACID; TRANSMEMBRANE G PROTEIN COUPLED RECEPTOR 5; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

AUTOIMMUNE CHOLESTATIC LIVER DISEASE; AUTOIMMUNE LIVER DISEASE; CHOLESTASIS; CYTOTOXICITY; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INTESTINE FLORA; NONHUMAN; REGULATORY MECHANISM; REVIEW; ADAPTIVE IMMUNITY; ANIMAL; AUTOIMMUNE DISEASE; BILIARY CIRRHOSIS; DISEASE EXACERBATION; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; SCLEROSING CHOLANGITIS;

ADAPTIVE IMMUNITY; ANIMALS; AUTOIMMUNE DISEASES; BILE ACIDS AND SALTS; CHOLANGITIS, SCLEROSING; CHOLESTASIS; DISEASE PROGRESSION; GASTROINTESTINAL MICROBIOME; HUMANS; LIVER CIRRHOSIS, BILIARY;

EID: 85025127280     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.07.002     Document Type: Review

References (196)

1. Chapman, R.W., Arborgh, B., Rhodes, J., Summerfield, J., Dick, R., Scheuer, P., et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 21 (1980), 870–877.
2. Lindor, K.D., Gershwin, M.E., Poupon, R., Kaplan, M., Bergasa, N.V., Heathcote, E.J., Primary biliary cirrhosis. Hepatology 50 (2009), 291–308.
3. Gershwin, M.E., Mackay, I.R., The causes of primary biliary cirrhosis: Convenient and inconvenient truths. Hepatology 47 (2008), 737–745.
4. Hirschfield, G.M., Karlsen, T.H., Lindor, K.D., Adams, D.H., Primary sclerosing cholangitis. Lancet 382 (2013), 1587–1599.
5. Takakura, W.R., Tabibian, J.H., Bowlus, C.L., The evolution of natural history of primary sclerosing cholangitis. Curr Opin Gastroenterol 33 (2017), 71–77.
6. Chung, B.K., Guevel, B.T., Reynolds, G.M., Gupta Udatha, D.B., Henriksen, E.K., Stamataki, Z., et al. Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis. J Autoimmun 77 (2017), 45–54.
7. Ji, S.G., Juran, B.D., Mucha, S., Folseraas, T., Jostins, L., Melum, E., et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet 49 (2017), 269–273.
8. Sarkar, S., Bowlus, C.L., Primary sclerosing cholangitis: multiple phenotypes, multiple approaches. Clin Liver Dis 20 (2016), 67–77.
9. He, X.S., Gershwin, M.E., Ansari, A.A., Checkpoint-based immunotherapy for autoimmune diseases - opportunities and challenges. J Autoimmun 79 (2017), 1–3.
10. Horsley-Silva, J.L., Carey, E.J., Lindor, K.D., Advances in primary sclerosing cholangitis. Lancet Gastroenterol Hepatol 1 (2016), 68–77.
11. Webb, G.J., Hirschfield, G.M., Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimmun 66 (2016), 25–39.
12. Webb, G.J., Siminovitch, K.A., Hirschfield, G.M., The immunogenetics of primary biliary cirrhosis: a comprehensive review. J Autoimmun 64 (2015), 42–52.
13. Wang, J., Yang, G., Dubrovsky, A.M., Choi, J., Leung, P.S., Xenobiotics and loss of tolerance in primary biliary cholangitis. World J Gastroenterol 22 (2016), 338–348.
14. Hirschfield, G.M., Siminovitch, K.A., Genetics in PBC: what do the “risk genes” teach us?. Clin Rev Allergy Immunol 48 (2015), 176–181.
15. Yang, F., Wang, Q., Wang, Z., Miao, Q., Xiao, X., Tang, R., et al. The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis. Clin Rev Allergy Immunol 50 (2016), 114–123.
16. Tanaka, A., Gershwin, M.E., Finding the cure for primary biliary cholangitis - still waiting. Liver Int 37 (2017), 500–502.
17. Corpechot, C., Primary biliary cirrhosis beyond ursodeoxycholic acid. Semin Liver Dis 36 (2016), 15–26.
18. Williamson, K.D., Chapman, R.W., New therapeutic strategies for primary sclerosing cholangitis. Semin Liver Dis 36 (2016), 5–14.
19. Goode, E.C., Rushbrook, S.M., A review of the medical treatment of primary sclerosing cholangitis in the 21st century[J]. Therapeutic advances in chronic disease 7:1 (2016), 68–85.
20. Pereira, S., Rhodes, J., Campbell, B., Kumar, D., Bain, I., Murphy, G., et al. Biliary lactoferrin concentrations are increased in active inflammatory bowel disease: a factor in the pathogenesis of primary sclerosing cholangitis?. Clin Sci 95 (1998), 637–644.
21. Eksteen, B., The gut-liver axis in primary sclerosing cholangitis. Clin Liver Dis 20 (2016), 1–14.
22. Ma, H.-D., Wang, Y.-H., Chang, C., Gershwin, M.E., Lian, Z.-X., The intestinal microbiota and microenvironment in liver. Autoimmun Rev 14 (2015), 183–191.
23. Begley, M., Gahan, C.G., Hill, C., The interaction between bacteria and bile. FEMS Microbiol Rev 29 (2005), 625–651.
24. Chiang, J.Y., Bile acids: regulation of synthesis. J Lipid Res 50 (2009), 1955–1966.
25. Schmucker, D.L., Ohta, M., Kanai, S., Sato, Y., Kitani, K., Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology 12 (1990), 1216–1221.
26. Liu, H.X., Keane, R., Sheng, L., Wan, Y.J., Implications of microbiota and bile acid in liver injury and regeneration. J Hepatol 63 (2015), 1502–1510.
27. Jansen, P.L., Ghallab, A., Vartak, N., Reif, R., Schaap, F.G., Hampe, J., et al. The ascending pathophysiology of cholestatic liver disease. Hepatology 65 (2017), 722–738.
28. Chen, W., Owsley, E., Yang, Y., Stroup, D., Chiang, J.Y., Nuclear receptor-mediated repression of human cholesterol 7α-hydroxylase gene transcription by bile acids. J Lipid Res 42 (2001), 1402–1412.
29. Allen, K., Jaeschke, H., Copple, B.L., Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol 178 (2011), 175–186.
30. Schoemaker, M.H., Conde de la Rosa, L., Buist-Homan, M., Vrenken, T.E., Havinga, R., Poelstra, K., et al. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 39 (2004), 1563–1573.
31. Perez, M.J., Briz, O., Bile-acid-induced cell injury and protection. World J Gastroenterol 15 (2009), 1677–1689.
32. Lemasters, J.J., Nieminen, A.-L., Qian, T., Trost, L.C., Elmore, S.P., Nishimura, Y., et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta Bioenerg 1366 (1998), 177–196.
33. Yin, X.-M., Ding, W.-X., Death receptor activation-induced hepatocyte apoptosis and liver injury. Curr Mol Med 3 (2003), 491–508.
34. Malhi, H., Kaufman, R.J., Endoplasmic reticulum stress in liver disease. J Hepatol 54 (2011), 795–809.
35. Faubion, W.A., Guicciardi, M.E., Miyoshi, H., Bronk, S.F., Roberts, P.J., Svingen, P.A., et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 103 (1999), 137–145.
36. Borgognone, M., Pérez, L.M., Basiglio, C.L., Ochoa, J.E., Roma, M.G., Signaling modulation of bile salt-induced necrosis in isolated rat hepatocytes. Toxicol Sci 83 (2005), 114–125.
37. Lemasters, J.J., Qian, T., He, L., Kim, J.-S., Elmore, S.P., Cascio, W.E., et al. Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy. Antioxid Redox Signal 4 (2002), 769–781.
38. Spivey, J.R., Bronk, S.F., Gores, G.J., Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium. J Clin Investig, 92, 1993, 17.
39. Beuers, U., Hohenester, S., de Buy Wenniger, L.J.M., Kremer, A.E., Jansen, P.L., Elferink, R.P., The biliary HCO3 − umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 52 (2010), 1489–1496.
40. − umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 55 (2012), 173–183.
41. Medina, J.F., Role of the anion exchanger 2 in the pathogenesis and treatment of primary biliary cirrhosis. Dig Dis 29 (2011), 103–112.
42. Hisamoto, S., Shimoda, S., Harada, K., Iwasaka, S., Onohara, S., Chong, Y., et al. Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis. J Autoimmun 75 (2016), 150–160.
43. Cai, S.-Y., Ouyang, X., Chen, Y., Soroka, C.J., Wang, J., Mennone, A., et al. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI Insight, 2, 2017.
44. Bleier, J.I., Katz, S.C., Chaudhry, U.I., Pillarisetty, V.G., Kingham, T.P., Shah, A.B., et al. Biliary obstruction selectively expands and activates liver myeloid dendritic cells. J Immunol 176 (2006), 7189–7195.
45. O'Brien, K.M., Allen, K.M., Rockwell, C.E., Towery, K., Luyendyk, J.P., Copple, B.L., IL-17A synergistically enhances bile acid–induced inflammation during obstructive cholestasis. Am J Pathol 183 (2013), 1498–1507.
46. Dawson, P.A., Lan, T., Rao, A., Bile acid transporters. J Lipid Res 50 (2009), 2340–2357.
47. Trauner, M., Meier, P.J., Boyer, J.L., Molecular pathogenesis of cholestasis. N Engl J Med 339 (1998), 1217–1227.
48. Zollner, G., Marschall, H.-U., Wagner, M., Trauner, M., Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm 3 (2006), 231–251.
49. Trauner, M., Halilbasic, E., Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 140:4 (2011), 1120–1125 e12.
50. Li, T., Chiang, J.Y., Nuclear receptors in bile acid metabolism. Drug Metab Rev 45 (2013), 145–155.
51. Torres, J., Bao, X., Iuga, A.C., Chen, A., Harpaz, N., Ullman, T., et al. Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia. Inflamm Bowel Dis 19 (2013), 275–282.
52. Modica, S., Petruzzelli, M., Bellafante, E., Murzilli, S., Salvatore, L., Celli, N., et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 142:2 (2012), 355–365 e4.
53. Kir, S., Zhang, Y., Gerard, R.D., Kliewer, S.A., Mangelsdorf, D.J., Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7a1 in vivo. J Biol Chem 287 (2012), 41334–41341.
54. Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C.L., McDonald, J.G., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2 (2005), 217–225.
55. Kong, B., Wang, L., Chiang, J.Y., Zhang, Y., Klaassen, C.D., Guo, G.L., Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 56 (2012), 1034–1043.
56. Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D.J., Suchy, F.J., Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 276 (2001), 28857–28865.
57. Kast, H.R., Goodwin, B., Tarr, P.T., Jones, S.A., Anisfeld, A.M., Stoltz, C.M., et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277 (2002), 2908–2915.
58. Boyer, J.L., Trauner, M., Mennone, A., Soroka, C.J., Cai, S.-Y., Moustafa, T., et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTα-OSTβ in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 290:6 (2006), G1124–G1130.
59. Denson, L.A., Sturm, E., Echevarria, W., Zimmerman, T.L., Makishima, M., Mangelsdorf, D.J., et al. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 121 (2001), 140–147.
60. Gadaleta, R.M., van Mil, S.W., Oldenburg, B., Siersema, P.D., Klomp, L.W., van Erpecum, K.J., Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. Biochim Biophys Acta Mol Cell Biol Lipids 1801 (2010), 683–692.
61. Mencarelli, A., Renga, B., Migliorati, M., Cipriani, S., Distrutti, E., Santucci, L., et al. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol 183 (2009), 6657–6666.
62. Eaton, J.E., Talwalkar, J.A., Lazaridis, K.N., Gores, G.J., Lindor, K.D., Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 145 (2013), 521–536.
63. Fan, M., Wang, X., Xu, G., Yan, Q., Huang, W., Bile acid signaling and liver regeneration. Biochim Biophys Acta Gene Regul Mech 1849 (2015), 196–200.
64. Limaye, P.B., Bowen, W.C., Orr, A.V., Luo, J., Tseng, G.C., Michalopoulos, G.K., Mechanisms of hepatocyte growth factor–mediated and epidermal growth factor–mediated signaling in transdifferentiation of rat hepatocytes to biliary epithelium. Hepatology 47 (2008), 1702–1713.
65. Keitel, V., Reich, M., Häussinger, D., TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis?. Clin Rev Allergy Immunol 48 (2015), 218–225.
66. Donepudi, A.C., Boehme, S., Li, F., Chiang, J.Y., G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. Hepatology 65.3 (2017), 813–827.
67. Wang, Y.D., Chen, W.D., Yu, D., Forman, B.M., Huang, W., The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology 54 (2011), 1421–1432.
68. Pols, T.W., Nomura, M., Harach, T., Sasso, G.L., Oosterveer, M.H., Thomas, C., et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 14 (2011), 747–757.
69. Keitel, V., Häussinger, D., Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol 36 (2012), 412–419.
70. Jones, H., Alpini, G., Francis, H., Bile acid signaling and biliary functions. Acta Pharm Sin B 5 (2015), 123–128.
71. Chascsa, D., Carey, E.J., Lindor, K.D., Old and new treatments for primary biliary cholangitis. Liver Int 37 (2017), 490–499.
72. Prieto, J., García, N., Martí-Climent, J.M., Peñuelas, I., Richter, J.A., Medina, J.F., Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 117 (1999), 167–172.
73. Rodrigues, C., Fan, G., Ma, X., Kren, B.T., Steer, C.J., A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Investig, 101, 1998, 2790.
74. Calmus, Y., Gane, P., Rouger, P., Poupon, R., Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 11 (1990), 12–15.
75. Hegade, V.S., Speight, R.A., Etherington, R.E., Jones, D.E., Novel bile acid therapeutics for the treatment of chronic liver diseases. Ther Adv Gastroenterol 9 (2016), 376–391.
76. Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P.R., et al. 6α-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 45 (2002), 3569–3572.
77. Floreani, A., Franceschet, I., Perini, L., Cazzagon, N., Gershwin, M.E., Bowlus, C.L., New therapies for primary biliary cirrhosis. Clin Rev Allergy Immunol 48 (2015), 263–272.
78. Nevens, F., Andreone, P., Mazzella, G., Strasser, S.I., Bowlus, C., Invernizzi, P., et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 375 (2016), 631–643.
79. Bowlus, C.L., Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection. Hepat Med 8 (2016), 89–95.
80. Mousa, H.S., Carbone, M., Malinverno, F., Ronca, V., Gershwin, M.E., Invernizzi, P., Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach. Autoimmun Rev 15 (2016), 870–876.
81. Pares, A., Novel treatment strategies for primary biliary cholangitis. Semin Liver Dis 37 (2017), 60–72.
82. Baghdasaryan, A., Fuchs, C.D., Österreicher, C.H., Lemberger, U.J., Halilbasic, E., Påhlman, I., et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J Hepatol 64 (2016), 674–681.
83. Fuchs, C.D., Paumgartner, G., Wahlström, A., Schwabl, P., Reiberger, T., Leditznig, N., et al. Metabolic preconditioning protects BSEP/ABCB11 −/− mice against cholestatic liver injury. J Hepatol 66 (2017), 95–101.
84. Trauner, M., Fuchs, C.D., Halilbasic, E., Paumgartner, G., New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Hepatology 65:4 (2017), 1393–1404.
85. Lozupone, C.A., Stombaugh, J.I., Gordon, J.I., Jansson, J.K., Knight, R., Diversity, stability and resilience of the human gut microbiota. Nature 489 (2012), 220–230.
86. Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K.S., Manichanh, C., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464 (2010), 59–65.
87. Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500 (2013), 541–546.
88. Hooper, D.U., Chapin, F., Ewel, J., Hector, A., Inchausti, P., Lavorel, S., et al. Effects of biodiversity on ecosystem functioning: a consensus of current knowledge. Ecol Monogr 75 (2005), 3–35.
89. Tilg, H., Cani, P.D., Mayer, E.A., Gut microbiome and liver diseases. Gut 65 (2016), 2035–2044.
90. Rosser, E.C., Mauri, C., A clinical update on the significance of the gut microbiota in systemic autoimmunity. J Autoimmun 74 (2016), 85–93.
91. Chen, B., Sun, L., Zhang, X., Integration of microbiome and epigenome to decipher the pathogenesis of autoimmune diseases. J Autoimmun, 2017 [Epub ahead of print].
92. Shamriz, O., Mizrahi, H., Werbner, M., Shoenfeld, Y., Avni, O., Koren, O., Microbiota at the crossroads of autoimmunity. Autoimmun Rev 15 (2016), 859–869.
93. Lerner, A., Matthias, T., Rheumatoid arthritis-celiac disease relationship: joints get that gut feeling. Autoimmun Rev 14 (2015), 1038–1047.
94. Rossen, N.G., Fuentes, S., Boonstra, K., D'Haens, G.R., Heilig, H.G., Zoetendal, E.G., et al. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis, 2015, jju023.
95. Lv, L.X., Fang, D.Q., Shi, D., Chen, D.Y., Yan, R., Zhu, Y.X., et al. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ Microbiol 18 (2016), 2272–2286.
96. Tang, R., Wei, Y., Li, Y., Chen, W., Chen, H., Wang, Q., et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut, 2017 [gutjnl-2016-313332; Epub ahead of print].
97. Lichtman, S.N., Keku, J., Clark, R.L., Schwab, J.H., Sartor, R.B., Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 13 (1991), 766–772.
98. Yamada, S., Ishii, M., Liang, L.S., Yamamoto, T., Toyota, T., Small duct cholangitis induced byn-formyll-methioninel-leucinel-tyrosine in rats. J Gastroenterol 29 (1994), 631–636.
99. Haruta, I., Kikuchi, K., Hashimoto, E., Nakamura, M., Miyakawa, H., Hirota, K., et al. Long-term bacterial exposure can trigger nonsuppurative destructive cholangitis associated with multifocal epithelial inflammation. Lab Invest 90 (2010), 577–588.
100. Tabibian, J.H., O'hara, S.P., Trussoni, C.E., Tietz, P.S., Splinter, P.L., Mounajjed, T., et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology 63 (2016), 185–196.
101. Ali, A.H., Carey, E.J., Lindor, K.D., The microbiome and primary sclerosing cholangitis. seminars in liver disease. 2016, Thieme Medical Publishers, 340–348.
102. Quigley, E.M., Primary biliary cirrhosis and the microbiome. Semin Liver Dis 36 (2016), 349–353.
103. Karlsen, T.H., Primary sclerosing cholangitis: 50 years of a gut–liver relationship and still no love?. Gut, 2016 [gutjnl-2016-312137].
104. Hooper, L.V., Littman, D.R., Macpherson, A.J., Interactions between the microbiota and the immune system. Science 336 (2012), 1268–1273.
105. Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., Medzhitov, R., Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118 (2004), 229–241.
106. Tabibian, J.H., O'hara, S.P., Lindor, K.D., Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol 49 (2014), 901–908.
107. Grant, A.J., Lalor, P.F., Salmi, M., Jalkanen, S., Adams, D.H., Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 359 (2002), 150–157.
108. Eksteen, B., Grant, A.J., Miles, A., Curbishley, S.M., Lalor, P.F., Hübscher, S.G., et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9 + gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 200 (2004), 1511–1517.
109. Seidel, D., Eickmeier, I., Kühl, A.A., Hamann, A., Loddenkemper, C., Schott, E., CD8 T cells primed in the gut-associated lymphoid tissue induce immune-mediated cholangitis in mice. Hepatology 59 (2014), 601–611.
110. Jimenez-Dalmaroni, M.J., Gerswhin, M.E., Adamopoulos, I.E., The critical role of toll-like receptors–from microbial recognition to autoimmunity: a comprehensive review. Autoimmun Rev 15 (2016), 1–8.
111. Shi, T.-Y., Zhang, F.-C., Role of autoimmunity in primary biliary cirrhosis. World J Gastroenterol 18 (2012), 7141–7148.
112. Bae, H.R., Leung, P.S., Tsuneyama, K., Valencia, J.C., Hodge, D.L., Kim, S., et al. Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology 64 (2016), 1189–1201.
113. Shuai, Z., Wang, J., Badamagunta, M., Choi, J., Yang, G., Zhang, W., et al. The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Hepatology 65:5 (2017), 1670–1682.
114. Zhang, J., Zhang, W., Leung, P.S., Bowlus, C.L., Dhaliwal, S., Coppel, R.L., et al. Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology 60 (2014), 1708–1716.
115. Rodriguez, E.A., Carey, E.J., Lindor, K.D., Emerging treatments for primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol 11 (2017), 451–459.
116. Wang, L., Wang, F.-S., Chang, C., Gershwin, M.E., Breach of tolerance: primary biliary cirrhosis. Seminars in liver disease. 2014, Thieme Medical Publishers, 297–317.
117. Chung, B.K., Guevel, B.T., Reynolds, G.M., Udatha, D.G., EKK, Henriksen, Stamataki, Z., et al. Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis. J Autoimmun 77 (2017), 45–54.
118. Sakaguchi, S., Naturally arising CD4 + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 (2004), 531–562.
119. Harada, K., Isse, K., Sato, Y., Ozaki, S., Nakanuma, Y., Endotoxin tolerance in human intrahepatic biliary epithelial cells is induced by upregulation of IRAK-M. Liver Int 26 (2006), 935–942.
120. Kita, H., Matsumura, S., He, X.-S., Ansari, A.A., Lian, Z.-X., Van de Water, J., et al. Quantitative and functional analysis of PDC-E2–specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest 109 (2002), 1231–1240.
121. Fussey, S., Ali, S.T., Guest, J.R., James, O., Bassendine, M.F., Yeaman, S.J., Reactivity of primary biliary cirrhosis sera with Escherichia coli dihydrolipoamide acetyltransferase (E2p): characterization of the main immunogenic region. Proc Natl Acad Sci 87 (1990), 3987–3991.
122. Burroughs, A.K., Butler, P., Sternberg, M., Baum, H., Molecular mimicry in liver disease. Nature, 358, 1992, 377.
123. Terjung, B., Söhne, J., Lechtenberg, B., Gottwein, J., Muennich, M., Herzog, V., et al. p-ANCAs in autoimmune liver disorders recognise human β-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 59 (2010), 808–816.
124. Michalek, R.D., Rathmell, J.C., The metabolic life and times of a T-cell. Immunol Rev 236 (2010), 190–202.
125. Fox, C.J., Hammerman, P.S., Thompson, C.B., Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 5 (2005), 844–852.
126. Willemsen, L., Koetsier, M., Van Deventer, S., Van Tol, E., Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E1 and E2 production by intestinal myofibroblasts. Gut 52 (2003), 1442–1447.
127. Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.A., Nakato, G., Takahashi, D., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504 (2013), 446–450.
128. Smith, P.M., Howitt, M.R., Panikov, N., Michaud, M., Gallini, C.A., Bohlooly-y, M., et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341 (2013), 569–573.
129. Usami, M., Kishimoto, K., Ohata, A., Miyoshi, M., Aoyama, M., Fueda, Y., et al. Butyrate and trichostatin A attenuate nuclear factor κB activation and tumor necrosis factor α secretion and increase prostaglandin E 2 secretion in human peripheral blood mononuclear cells. Nutr Res 28 (2008), 321–328.
130. Chang, P.V., Hao, L., Offermanns, S., Medzhitov, R., The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci 111 (2014), 2247–2252.
131. Singh, N., Thangaraju, M., Prasad, P.D., Martin, P.M., Lambert, N.A., Boettger, T., et al. Blockade of dendritic cell development by bacterial fermentation products butyrate and propionate through a transporter (Slc5a8)-dependent inhibition of histone deacetylases. J Biol Chem 285 (2010), 27601–27608.
132. Eksteen, B., Mora, J.R., Haughton, E.L., Henderson, N.C., Lee–Turner, L., Villablanca, E.J., et al. Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells. Gastroenterology 137 (2009), 320–329.
133. Iwata, M., Hirakiyama, A., Eshima, Y., Kagechika, H., Kato, C., Song, S.-Y., Retinoic acid imprints gut-homing specificity on T cells. Immunity 21 (2004), 527–538.
134. Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331 (2011), 337–341.
135. Ivanov, I.I., Atarashi, K., Manel, N., Brodie, E.L., Shima, T., Karaoz, U., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139 (2009), 485–498.
136. Gaboriau-Routhiau, V., Rakotobe, S., Lécuyer, E., Mulder, I., Lan, A., Bridonneau, C., et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31 (2009), 677–689.
137. Atarashi, K., Tanoue, T., Ando, M., Kamada, N., Nagano, Y., Narushima, S., et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell 163 (2015), 367–380.
138. Folseraas, T., Melum, E., Rausch, P., Juran, B.D., Ellinghaus, E., Shiryaev, A., et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol 57 (2012), 366–375.
139. Rankin, J., Boden, R., Goulston, S., Morrow, W., The liver in ulcerative colitis treatment of pericholangitis with tetracycline. Lancet 274 (1959), 1110–1112.
140. Tabibian, J.H., Talwalkar, J.A., Lindor, K.D., Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int, 2013, 2013.
141. Blaser, M.J., Antibiotic use and its consequences for the normal microbiome. Science 352 (2016), 544–545.
142. Watanabe, M., Fukiya, S., Yokota, A., Comprehensive evaluation of the bactericidal activities of free bile acids in the large intestine of humans and rodents. J Lipid Res 58:6 (2017), 1143–1152.
143. Bernstein, H., Payne, C.M., Bernstein, C., Schneider, J., Beard, S.E., Crowley, C.L., Activation of the promoters of genes associated with DNA damage, oxidative stress, ER stress and protein malfolding by the bile salt, deoxycholate. Toxicol Lett 108 (1999), 37–46.
144. Cremers, C.M., Knoefler, D., Vitvitsky, V., Banerjee, R., Jakob, U., Bile salts act as effective protein-unfolding agents and instigators of disulfide stress in vivo. Proc Natl Acad Sci 111:16 (2014), E1610–E1619.
145. Clements, W., Parks, R., Erwin, P., Halliday, M., Barr, J., Rowlands, B., Role of the gut in the pathophysiology of extrahepatic biliary obstruction. Gut 39 (1996), 587–593.
146. Inagaki, T., Moschetta, A., Lee, Y.-K., Peng, L., Zhao, G., Downes, M., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 103 (2006), 3920–3925.
147. D'Aldebert, E., Mve, M.J.B.B., Mergey, M., Wendum, D., Firrincieli, D., Coilly, A., et al. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 136 (2009), 1435–1443.
148. Devkota, S., Chang, E.B., Interactions between diet, bile acid metabolism, gut microbiota, and inflammatory bowel diseases. Dig Dis 33 (2015), 351–356.
149. Gahan, C.G., Hill, C., Listeria monocytogenes: survival and adaptation in the gastrointestinal tract. Front Cell Infect Microbiol, 4, 2014, 9.
150. Kakiyama, G., Pandak, W.M., Gillevet, P.M., Hylemon, P.B., Heuman, D.M., Daita, K., et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 58 (2013), 949–955.
151. Van Eldere, J., Celis, P., De Pauw, G., Lesaffre, E., Eyssen, H., Tauroconjugation of cholic acid stimulates 7 alpha-dehydroxylation by fecal bacteria. Appl Environ Microbiol 62 (1996), 656–661.
152. Ridlon, J.M., Kang, D.-J., Hylemon, P.B., Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47 (2006), 241–259.
153. Ridlon, J.M., Hylemon, P.B., Identification and characterization of two bile acid coenzyme A transferases from Clostridium scindens, a bile acid 7α-dehydroxylating intestinal bacterium. J Lipid Res 53 (2012), 66–76.
154. Wahlström, A., Sayin, S.I., Marschall, H.-U., Bäckhed, F., Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 24 (2016), 41–50.
155. Ridlon, J.M., Kang, D.J., Hylemon, P.B., Bajaj, J.S., Bile acids and the gut microbiome. Curr Opin Gastroenterol, 30, 2014, 332.
156. Kisiela, M., Skarka, A., Ebert, B., Maser, E., Hydroxysteroid dehydrogenases (HSDs) in bacteria–a bioinformatic perspective. J Steroid Biochem Mol Biol 129 (2012), 31–46.
157. Gonzalez, F.J., Jiang, C., Xie, C., Patterson, A.D., Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease. Dig Dis 35 (2017), 178–184.
158. Li, T., Chiang, J.Y., Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 66 (2014), 948–983.
159. Sayin, S.I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17 (2013), 225–235.
160. Kim, I., Ahn, S.-H., Inagaki, T., Choi, M., Ito, S., Guo, G.L., et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 48 (2007), 2664–2672.
161. Degirolamo, C., Rainaldi, S., Bovenga, F., Murzilli, S., Moschetta, A., Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep 7 (2014), 12–18.
162. Martoni, C.J., Labbé, A., Ganopolsky, J.G., Prakash, S., Jones, M.L., Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. reuteri NCIMB 30242. Gut Microbes 6 (2015), 57–65.
163. Badman, M.K., Desai, S., Laffitte, B., Decristofaro, M., Lin, T., Chen, J., et al. First-in-human experience with LJN452, an orally available non-bile acid FXR agonist, demonstrates potent activation of FXR in healthy subjects. Hepatology, 2016, Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ USA, 16A-7A.
164. Schwabl, P., Hambruch, E., Supper, P., Burnet, M., Peck-Radosavljevic, M., Reiberger, T., et al. The non-steroidal Fxr agonist Gs-9674 reduces liver fibrosis and ameliorates portal hypertension in a rat nash model. J Hepatol 64:2 (2016), S165–S166.
165. Baghdasaryan, A., Claudel, T., Gumhold, J., Silbert, D., Adorini, L., Roda, A., et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2 −/−(Abcb4 −/−) mouse cholangiopathy model by promoting biliary HCO 3 − output. Hepatology 54 (2011), 1303–1312.
166. Cipriani, S., Renga, B., D'Amore, C., Simonetti, M., De Tursi, A.A., Carino, A., et al. Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling. PLoS One, 10, 2015, e0129866.
167. Mayo, M.J., Wigg, A.J., Roberts, S.K., Arnold, H., Hassanein, T.I., Leggett, B.A., et al. NGM282, a novel variant of FGF-19, demonstrates biologic activity in primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid: results of a phase 2 multicenter, randomized, double blinded, placebo controlled trial. Hepatology 62 (2015), 263A–264A.
168. Álvarez-Sola, G., Uriarte, I., Latasa, M., Elizalde, M., Urtasun, R., Rodríguez-Ortigosa, C., et al. Development of a new hepatoprotective and proregenerative molecule based on fibroblast growth factor 15/19. J Hepatol, 64, 2016, S184.
169. Ghonem, N.S., Assis, D.N., Boyer, J.L., Fibrates and cholestasis. Hepatology 62 (2015), 635–643.
170. Hosonuma, K., Sato, K., Yamazaki, Y., Yanagisawa, M., Hashizume, H., Horiguchi, N., et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol 110 (2015), 423–431.
171. Mayo, M., Pockros, P., Jones, D., Bowlus, C., Levy, C., Patanwala, I., et al. Clarity: a phase 2, randomized, double-blind, placebo-controlled study of Lopixibat chloride (formerly Lum001), a novel apical sodium-dependent bile acid transporter inhibitor, in the treatment of primary biliary cirrhosis associated with itching. J Hepatol, 64, 2016, S197.
172. Hegade, V.S., Kendrick, S.F., Dobbins, R.L., Miller, S.R., Thompson, D., Richards, D., et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet 389:10074 (2017), 1114–1123.
173. Miethke, A.G., Zhang, W., Simmons, J., Taylor, A.E., Shi, T., Shanmukhappa, S.K., et al. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology 63 (2016), 512–523.
174. Slijepcevic, D., Kaufman, C., Wichers, C.G., Gilglioni, E.H., Lempp, F.A., Duijst, S., et al. Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na +-taurocholate cotransporting polypeptide knockout mice. Hepatology 62 (2015), 207–219.
175. Trauner, M.H., Fickert, P., Hirschfield, G., Denk, G., Altorjay, I., Marschall, H.-U., et al. norUrsodeoxycholic acid (norUDCA) improves cholestasis in primary sclerosing cholangitis (PSC) independent of ursodeoxycholic acid (UDCA) pre-treatment and response. Hepatology, 2016, WB Saunders, 111A-A.
176. Liver EAFTSOT, EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 51 (2009), 237–267.
177. Kuiper, E.M., van Erpecum, K.J., Beuers, U., Hansen, B.E., Thio, H.B., de Man, R.A., et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 52 (2010), 1334–1340.
178. Kevans, D., Tyler, A.D., Holm, K., Jørgensen, K.K., Vatn, M.H., Karlsen, T.H., et al. Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis. J Crohns Colitis 10 (2016), 330–337.
179. Torres, J., Bao, X., Goel, A., Colombel, J.F., Pekow, J., Jabri, B., et al. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther 43 (2016), 790–801.
180. Kummen, M., Holm, K., Anmarkrud, J.A., Nygård, S., Vesterhus, M., Høivik, M.L., et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 66:4 (2017), 611–619.
181. Sabino, J., Vieira-Silva, S., Machiels, K., Joossens, M., Falony, G., Ballet, V., et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 65 (2016), 1681–1689.
182. Rühlemann, M.C., Heinsen, F.-A., Zenouzi, R., Lieb, W., Franke, A., Schramm, C., Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. Gut 66:4 (2017), 753–754.
183. Quraishi, M.N., Sergeant, M., Kay, G., Iqbal, T., Chan, J., Constantinidou, C., et al. The gut-adherent microbiota of PSC–IBD is distinct to that of IBD. Gut 66 (2017), 386–388.
184. Mistilis, S., Skyring, A., Goulston, S., Effect of long-term tetracycline therapy, steroid therapy and colectomy in pericholangitis associated with ulcerative colitis. Australas Ann Med 14 (1965), 286–294.
185. Ghent, C.N., Carruthers, S.G., Treatment of pruritus in primary biliary cirrhosis with rifampin: results of a double-blind, crossover, randomized trial. Gastroenterology 94 (1988), 488–493.
186. Bachs, L., Parés, A., Elena, M., Piera, C., Rodés, J., Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102 (1992), 2077–2080.
187. Kozaiwa, K., Tajiri, H., Sawada, A., Tada, K., Etani, Y., Miki, K., et al. Case report: three paediatric cases of primary sclerosing cholangitis treated with ursodeoxycholic acid and sulphasalazine. J Gastroenterol Hepatol 13 (1998), 825–829.
188. Tada, S., Ebinuma, H., Saito, H., Hibi, T., Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis. J Gastroenterol 41 (2006), 388–389.
189. Cox, K.L., Cox, K.M., Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 27 (1998), 580–583.
190. Tabibian, J., Weeding, E., Jorgensen, R., Petz, J., Keach, J., Talwalkar, J.A., et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis-a pilot study. Aliment Pharmacol Ther 37 (2013), 604–612.
191. Färkkilä, M., Karvonen, A.L., Nurmi, H., Nuutinen, H., Taavitsainen, M., Pikkarainen, P., et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 40 (2004), 1379–1386.
192. Boner, A., Peroni, D., Bodini, A., Delaini, G., Piacentini, G., Azithromycin may reduce cholestasis in primary sclerosing cholangitis: a case report and serendipitous observation. Int J Immunopathol Pharmacol 20 (2007), 847–849.
193. Silveira, M.G., Torok, N.J., Gossard, A.A., Keach, J.C., Jorgensen, R.A., Petz, J.L., et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 104 (2009), 83–88.
194. Tabibian, J.H., Gossard, A., El-Youssef, M., Eaton, J.E., Petz, J., Jorgensen, R., et al. Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis. Am J Ther 24:1 (2017), e56–e63.
195. Vleggaar, F.P., Monkelbaan, J.F., van Erpecum, K.J., Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol 20 (2008), 688–692.
196. Shimizu, M., Iwasaki, H., Mase, S., Yachie, A., Successful treatment of primary sclerosing cholangitis with a steroid and a probiotic. Case Rep Gastroenterol 6 (2012), 249–253.